-

Derma­tology beyond the skin

111 years of building, sharing and reinvesting in knowledge

1908 in Denmark

Founded and headquartered in Denmark, currently employing 6,000 professionals across 61 countries.

+130 countries

Supplying treatments to people with medical needs in more than 130 countries around the world.

125 million lives

Striving to positively impact the lives of 125 million people through medical dermatology by 2025.
Learn More
IMPORTANT UPDATE

Updates regarding COVID-19

As the COVID-19 situation continues to evolve globally, LEO Pharma is acting to support the health and safety of our employees and to activate our business continuity plans. We stay committed to bring an uninterrupted supply of medicines for patients around the world.
Read the full story

Our performance and results

LEO Pharma’s annual report covers our financial performance as well as our CSR reporting for the financial year from January 1 to December 31.
Read our 2019 annual report
CAREER

Find out how we pioneer together

For us, pioneering together is about constantly improving and extending what’s possible for each other, our company, and our patients.
Learn more
NEWS ARTICLE

LEO Pharma Enters License Agreement with Oneness Biotech and Microbio Shanghai for FB825 a Novel Atopic Dermatitis and Asthma Drug Candidate

LEO Pharma A/S, a global leader in medical dermatology, today announced that is has signed a worldwide exclusive licensing agreement with Oneness Biotech (Taiwan, TPEx: 4743) and Microbio Shanghai (China) covering the development and commercialization of the novel Atopic Dermatitis (AD) and Allergic Asthma drug candidate, FB825.
BALLERUP, Denmark, April 15, 2020
Read the full story